TCP1 epsilon (CCT5) Human shRNA Plasmid Kit (Locus ID 22948)
CAT#: TL314115
CCT5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
Product images
CNY 6,281.00
CNY 4,070.00
Specifications
Product Data | |
Product Name | TCP1 epsilon (CCT5) Human shRNA Plasmid Kit (Locus ID 22948) |
Locus ID | 22948 |
UniProt ID | P48643 |
Synonyms | CCT-epsilon; CCTE; HEL-S-69; PNAS-102; TCP-1-epsilon |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | CCT5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 22948). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_001306153, NM_001306154, NM_001306155, NM_001306156, NM_012073, NM_012073.1, NM_012073.2, NM_012073.3, NM_012073.4, BC035499, BC002971, BC006543, BC009454, BC040027, NM_012073.5 |
Summary | The protein encoded by this gene is a molecular chaperone that is a member of the chaperonin containing TCP1 complex (CCT), also known as the TCP1 ring complex (TRiC). This complex consists of two identical stacked rings, each containing eight different proteins. Unfolded polypeptides enter the central cavity of the complex and are folded in an ATP-dependent manner. The complex folds various proteins, including actin and tubulin. Mutations in this gene cause hereditary sensory and autonomic neuropathy with spastic paraplegia (HSNSP). Alternative splicing results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 5 and 13. [provided by RefSeq, Apr 2015] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Documents
Product Manuals |
FAQs |
SDS |